Skip to content

Amgen

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile7 entries

  1. 2026

    France recalls Tavneos batches after deaths linked in Japan

    Recall announced

    France's medicine safety agency ANSM said the recall of all Tavneos batches available in France would begin on August 19, after the drug, made by U.S. biotech firm Amgen and sold by partner companies worldwide, was linked to 20 deaths in Japan. The European Commission had revoked the drug's marketing authorisation earlier in the month.

    Company response

    • Recall — France's medicine safety agency ANSM

      "The recall of all batches available in France will begin on August 19," France's medicine safety agency ANSM said in a statement.

    Source excerpt

    • The European Commission revoked the drug's marketing authorisation earlier this month because "the benefits are no longer proven to outweigh its risks".
    • Kissei Pharmaceutical, which sells the drug in Japan, said in May that 20 deaths had been reported among people using the it since 2022.
    • A drug called Tavneos used to treat rare autoimmune diseases will be pulled from the shelves in France, the country's medicine watchdog said Wednesday, after it was linked to 20 deaths in Japan.
  2. 2024

    Amgen sues Colorado over drug price board

    Lawsuit filed

    Amgen filed a lawsuit against Colorado concerning actions by the state Prescription Drug Affordability Board regarding Enbrel. According to the reported filing, Amgen argued that the board's actions are unconstitutional. The company sought to overturn decisions about the drug and to strike down parts of the law establishing the board.

    Amgen filed a lawsuit against Colorado over the state Prescription Drug Affordability Board’s actions concerning Enbrel, arguing that the board’s actions are unconstitutional and seeking to overturn decisions about the drug and strike down parts of the law establishing the board.

    Company response

    • Clarification — Amgen

      “We have significant concerns with the Colorado Prescription Drug Affordability Board’s decision to move forward with its flawed policy and process,” Amgen said in a statement. “There is no legal basis for the Board’s actions or haphazard process throughout the review period.”

    Source excerpt

    • In a lawsuit filed Friday in U.S. District Court in Denver, Amgen argues that the actions of Colorado’s Prescription Drug Affordability Board are unconstitutional because they conflict with federal laws and because they violate rights to due process.
    • The company is seeking not just to overturn the board’s recent decisions about Enbrel but also to strike down major parts of the law creating the board.
    • Amgen says the law also potentially interferes with Medicare’s ability to control its pricing decisions.
  3. 2024

    Sandoz and Amgen settle US denosumab patent disputes

    Settlement

    Sandoz announced an agreement with Amgen resolving patent disputes concerning Sandoz's FDA-approved denosumab biosimilars. The agreement permits Sandoz to enter the US market with biosimilar versions of Prolia and Xgeva on May 31, 2025, or earlier under specified circumstances.

    Source excerpt

    • Under the terms of the agreement, Sandoz may enter the US market with a biosimilar version of Prolia® and Xgeva® on May 31, 2025, or earlier under certain circumstances if customary acceleration provisions are triggered.
    • Patent infringement proceedings were initially filed by Amgen in the US Federal District Court for the District of New Jersey in May of 2023 pursuant to the Biologics Price Competition and Innovation Act (BPCIA).
    • Basel, April 30, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that it has reached agreement with Amgen to resolve all patent disputes between the two companies relating to the US Food and Drug Administration (FDA)-approved Sandoz denosumab biosimilars.
  4. 2023

    FTC sues to block Amgen's acquisition of Horizon Therapeutics

    Lawsuit filed

    The U.S. Federal Trade Commission filed a lawsuit to stop Amgen's proposed $27.8 billion acquisition of Horizon Therapeutics. The FTC said it was concerned Amgen could use its leading drugs to pressure insurers and pharmacy benefit managers to grant favorable terms for Horizon products. Amgen said it was disappointed and disputed that the deal raised legitimate competitive issues.

    Company response

    • Denial — Amgen

      Amgen said in a statement it was disappointed by the FTC decision and that it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues.

    Source excerpt

    • The US Federal Trade Commission has said it will sue to stop Amgen's $27.8 billion acquisition of Horizon Therapeutics in a rare move to block a large pharmaceutical deal.
    • In its complaint, the FTC said Amgen would be able to use the powerful position it has with insurance companies and pharmacy benefit managers due to its blockbuster drugs to pressure them into favorable terms for Horizon's two key products - the fast-growing thyroid eye disease treatment Tepezza and gout drug Krystexxa.
    • Amgen said in a statement it was disappointed by the FTC decision and that it believed it had "overwhelmingly demonstrated" that the deal had no legitimate competitive issues.
  5. 2023

    Amgen sues Novartis and Sandoz over proposed biosimilars

    Lawsuit filed

    Amgen filed a lawsuit against Novartis and its Sandoz business in federal court in New Jersey, alleging that Sandoz's proposed versions of Prolia and Xgeva infringe patents. Amgen requested that the court block the biosimilars until its patents expire. The dispute concerns proposed biosimilar products and patent protection for Prolia and Xgeva.

    Amgen sued Novartis and its Sandoz business in federal court in New Jersey, accusing Sandoz's proposed versions of Prolia and Xgeva of infringing patents. Amgen asked the court to block the biosimilars until its patents expire.

    Source excerpt

    • Amgen asked the court to block Sandoz's biosimilars of the drugs until its patents expire.
    • Amgen Inc sued Novartis AG's Sandoz in New Jersey federal court Monday, accusing Sandoz's proposed versions of its multibillion-dollar bone-strengthening drugs Prolia and Xgeva of infringing several patents.
    • The plaintiffs are seeking a declaration that Amgen infringed upon the ‘421, ‘158 and ‘149 patents, actual damages, interest, attorney’s fees and costs, and other relief.
  6. 2021

    Amgen files Supreme Court petition in patent dispute

    Lawsuit filed

    Amgen Inc. and its subsidiaries filed a petition for certiorari with the U.S. Supreme Court against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC. The petition concerns the written-description requirement for patents and the level of detail that requirement demands.

    Source excerpt

    • On Monday a petition for certiorari was filed to the Supreme Court of the United States by Amgen Inc. and its subsidiaries against Sanofi Aventisub LLC, Regeneron Pharmaceuticals Inc. and Sanofi-Aventis US, LLC.
  7. 2012

    Off-label promotion, kickbacks, and pricing settlement

    Amgen pleaded guilty to a federal charge and paid $762 million to resolve criminal and civil allegations concerning promotion of medicines for unapproved uses, improper inducements, and false pricing submissions.